Amgen stock gains as MariTide concerns addressed AMGN:NASDAQ
Published on November 13, 2024
Shares of Amgen Inc. (NASDAQ:AMGN) saw a boost in trading after the company addressed concerns regarding its MariTide drug. MariTide, which is used to treat certain types of cancer, had come under scrutiny due to potential bone safety issues linked to obesity. However, Amgen quickly denied these concerns, stating that they have conducted extensive studies and found no evidence of increased risk. This reassurance has led to a positive response from investors, resulting in a gain in the company's stock value. For individuals interested in investing in Amgen, it is recommended to seek the guidance of professionals from Stocks Prognosis to get a better understanding of the future movement of the company's stock.
Investor opinions & comments
To leave a comment, you need to Login or Register.
ProfitPam
November 17, 2024 at 15:10
I'm really glad to hear that Amgen has addressed the concerns about MariTide. I believe this drug has great potential in treating cancer, and I'm interested in investing in Amgen's stock
CashCaleb
November 17, 2024 at 14:30
Amgen's denial seems too convenient. It's always worrisome when a company denies any risks associated with its products. I'll wait for more evidence before trusting their statement
NicholasEdwards
November 17, 2024 at 13:39
Investing in Amgen seems like a safe bet considering the swift response and reassurance they provided. I have faith in the company's ability to overcome any challenges
CharlotteCampbell
November 17, 2024 at 12:48
Great news for Amgen! The quick response and reassurance from the company shows their commitment to addressing concerns and maintaining the trust of investors
MeganThompson
November 16, 2024 at 13:54
This news is reassuring and shows that Amgen is dedicated to ensuring the safety and effectiveness of their drugs. I'm considering investing in their stock
SmartSophie
November 15, 2024 at 10:33
The fact that Amgen conducted extensive studies and found no evidence of increased risk is definitely a positive sign. It shows they prioritize patient safety
OliverHayes
November 14, 2024 at 16:28
I'm happy to see that Amgen is proactive in addressing the concerns about MariTide. This will definitely help maintain investor confidence in the company
MaryJohnson
November 14, 2024 at 15:54
I've been following Amgen for a while now, and this news is definitely encouraging. I think their stock value will continue to rise
FinanceDave
November 14, 2024 at 06:54
I'm not convinced by Amgen's quick denial of the concerns. It feels like they're just trying to protect their stock value. I'll wait for more credible information before considering investing
IsaacPerry
November 14, 2024 at 00:36
Is Amgen's denial of the bone safety concerns backed by independent research? It's important to know the credibility of their studies before making any investment decisions